Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study
Authors:
- Elena PettiniEPElena Pettini
- Annalisa CiabattiniACAnnalisa Ciabattini
- Fabio FiorinoFabio Fiorino
- Jacopo PolvereJPJacopo Polvere
- Gabiria PastoreGPGabiria Pastore
- Monica TozziMTMonica Tozzi
- Francesca MontagnaniFMFrancesca Montagnani
- Giuseppe MarottaGMGiuseppe Marotta
- Alessandro BucalossiABAlessandro Bucalossi
- Donata MedagliniDMDonata Medaglini
Open Access
Abstract
Preventing SARS-CoV-2 infection is of utmost importance in allogeneic hematopoietic cell transplantation patients (allo-HCT), given their heightened susceptibility to adverse outcomes associated with SARS-CoV-2 infection. However, limited data are available regarding the immune response to COVID-19 vaccines in these subjects, particularly concerning the generation and persistence of spike-specific memory response. Here, we analyzed the spike-specific memory B cells in a cohort of allo-HCT recipients vaccinated with multiple doses of the mRNA-1273 vaccine and monitored the spike-specific antibody response from baseline up to one month after the fourth dose. After the primary vaccine series, the frequency of spike-specific B cells, detected within the pool of Ig-switched CD19+ cells, significantly increased. The booster dose further induced a significant expansion, reaching up to 0.28% of spike-specific B cells. The kinetics of this expansion were slower in the allo-HCT recipients compared to healthy controls. Spike-specific IgG and ACE2/RBD binding inhibition activity were observed in 80% of the allo-HCT recipients after the first two doses, with a significant increase after the third and fourth booster doses, including in the subjects who did not respond to the primary vaccine series. Additionally, 87% of the allo-HCT recipients exhibited positive cross-inhibition activity against the BA.1 variant. Our findings provide evidence that allo-HCT recipients need repeated doses of the mRNA-1273 vaccine to induceSARS-CoV-2 specific immune response similar to that observed in healthy individuals. This is particularly crucial for vulnerable individuals who may exhibit a limited response to the primary series of SARS-CoV-2 vaccination.Keywords
Funding Information
- University of Siena (PNRR PE13 INF_ACT-CUP B63C22001400007)
- Department of Medical Biotechnology (PNRR PE13 INF_ACT-CUP B63C22001400007)
This publication has 35 references indexed in Scilit:
- Predictors of impaired antibody response after SARS‐CoV‐2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational studyAmerican Journal of Hematology, 2022
- COVID-19 and HSCT (Hematopoietic stem cell transplant)Best Practice & Research Clinical Haematology, 2022
- SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapiesBlood Reviews, 2022
- Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantationInternational Journal of Hematology, 2022
- Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individualsCell, 2022
- Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike proteinJournal of Medical Virology, 2021
- Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2017
- Vaccinations in patients with hematological malignanciesBlood Reviews, 2016
- Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2015
- A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic TransplantationTransplantation and Cellular Therapy, 2013